Best places to work

Glassdoor recognizes NIH as one of the best places to work

Dec 31, 2018

NIH has been recognized as one of the best places to work by Glassdoor and the Partnership for Public Service. Glassdoor rankings were “determined by the people who know these companies best - their employees.” The Partnership for Public Service rankings were determined by the views of more than 847,000 civil servants from 488 federal organizations on a wide range of workplace topics. Read more...

NCI connect

View the new NCI-CONNECT video on YouTube

Dec 27, 2018

NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) aims to advance the understanding of rare adult central nervous system (CNS) cancers by establishing and fostering patient-advocacy-provider partnerships and networks to improve approaches to care and treatment. Learn more about NCI-CONNECT through this new video. Read more...

Horizons cover

New CCR publication, Horizons, is now available

Dec 18, 2018

As Nobel-Prize-winning physicist Niels Bohr once said, “Prediction is very difficult, especially about the future.” Yet, several areas of research that promise new understanding and treatments of cancer are coming into view. In this magazine, we highlight several areas of investigation likely to shape future research conducted in CCR. The collection in Horizons is by no means complete but seeks to capture some of the major areas that will influence our future work. Read more...

Human T-cell leukemia virus

Renewed research focus on the human T-cell leukemia virus

Nov 9, 2018

Human T-cell leukemia virus-1(HTLV-1) is the only known retrovirus to directly cause cancer in humans. Infection with this retrovirus affects millions of people worldwide, but currently there is neither a targeted antiretroviral therapy nor a vaccine available. “The discovery of novel preventive or therapeutic remedies for this retrovirus could relieve not only the suffering of HTLV-1 infected individuals but also augment understanding of other chronic infections with cancer viruses,” says Genoveffa Franchini, M. D., Senior Investigator in the CCR Vaccine Branch who has conducted pioneering work on the retrovirus. Read more...

Perwez Hussain

Recap: The 5th NCI Pancreatic Cancer Symposium

Oct 15, 2018

The 5th NCI Pancreatic Cancer Symposium took place on October 2-3, 2018, and was attended by about 300 participants from across the United States and abroad. This year’s symposium was jointly organized by the NCI Pancreatic Cancer Interest Group and the Medical University of Gottingen, Germany. The symposium covered the latest advancements in the field and provided novel insights in the area of early detection, epidemiology, tumor biology including metabolic reprograming and inflammatory/immune signaling and tumor stromal interaction, and it highlighted the challenges in developing treatment strategies to improve patient outcomes.  Read more...

Steven Pavletic

Steven Pavletic elected as corresponding member of the Croatian Academy of Arts and Sciences

Jun 28, 2018

Steven Pavletic, M.D., Senior Clinician in the Experimental Transplantation and Immunology Branch, has been elected as a corresponding member of the Croatian Academy of Sciences and Arts. Dr. Pavletic was honored during a ceremony on June 14 at the Palace of the Academy in Zagreb, Croatia. Read more...

Killer T cell

CCR: A history of advancing the field of immunology

Jun 26, 2018

The Center for Cancer Research has been at the forefront in the field of immunology and immunotherapy for decades. Our scientists have made seminal findings that have opened doors to new research areas and treatment approaches for cancer patients. Use this timeline to explore our rich history at the cutting edge of research towards understanding the immune system and harnessing its power to treat cancer. Read more...

VHL

25 years ago: CCR scientists discover first gene linked to kidney cancer

May 29, 2018

Twenty-five years ago, NCI scientists uncovered the VHL gene, a gene whose mutation can lead to the development of kidney tumors. The discovery, the result of a decade-long partnership between CCR scientists, including W. Marston Linehan, M.D., Chief of CCR’s Urologic Oncology Branch, and families affected by the disease, paved the way for new targeted therapies that have improved the prognosis for patients with advanced kidney cancers.  Read more...

brain tumor facebook live

Facebook Live: Adult brain and spine tumor research and treatment

May 23, 2018

Please join us for a Facebook Live on adult brain and spine tumor research and treatment May 25 at 11:00 a.m. ET.. The conversation will focus on primary central nervous system (CNS) tumors, meaning the tumor begins in the brain or spinal cord. Mark Gilbert, M.D., Chief, and Terri Armstrong, M.D., Senior Investigator, both from the Neuro-Oncology Branch, will be joined by moderator and Chief Executive Officer, David Arons, of the National Brain Tumor Society.  Read more...

Travis

FDA grants orphan drug status to selumetinib for neurofibromatosis type 1 (NF1) treatment

Apr 23, 2018

The U.S. Food and Drug Administration granted orphan drug status in February to selumetinib for use in patients with the genetic disorder neurofibromatosis type 1 (NF1), who often develop tumors of the peripheral nervous system. Receiving orphan drug designation is a helpful step for selumetinib. Read more...

Pages